Nalmefene Injection (Zurnal) and Intranasal Nalmefene HCl (Opvee)

The U.S. Food and Drug Administration has approved the first nalmefene autoinjector for the emergency treatment of known or suspected opioid overdose. Nalmefene is an opioid antagonist and an analog of naltrexone. It was granted a priority review and accelerated approval with a breakthrough therapy designation. It is distributed by Purdue Pharma L.P. as Zurnal.